US Patent Issued to Novartis on March 18 for "Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl-6-[(3R)-3-hydroxypyrrolidin-1-yl-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide" (Swiss, American, French Inventors)

ALEXANDRIA, Va., March 19 -- United States Patent no. 12,252,479, issued on March 18, was assigned to Novartis AG (Basel, Switzerland).

"Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl-6-[(3R)-3-hydroxypyrrolidin-1-yl-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide" was invented by Stephanie Kay Dodd (Ayer, Mass.), Arnaud Grandeury (Helfrantzkirch, France), Emmanuel Suffert (Basel, Switzerland) and Evgenia Rousaki (Basel, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for pr...